Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

K Hicks, J; Bishop, JR; Sangkuhl, Katrin; Dj, Müller; Ji, Yuan; Leckband, SG; Leeder, JS; Graham, RL; Chiulli, DL; LLerena, Adrián; Skaar, TC; A. Scott, Stuart; Stingl, Julia; E. Klein, Teri; Caudle, KE; Gaedigk, Andrea

doi:10.1002/cpt.147

Public

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Published in Clinical Pharmacology & Therapeutics • May 13, 2015

Authors:

J K Hicks

JR Bishop

Katrin Sangkuhl

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting...

Subject

Fluvoxamine

Escitalopram

Citalopram

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!